PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
0.38%
Net income growth 0-5% – Slight. Howard Marks would worry about possible stagnation in bottom-line profitability.
3.11%
D&A up to 5% yoy – Manageable. Seth Klarman would see normal expansions if revenue justifies the extra depreciation.
-10.59%
A negative yoy change in deferred tax might cut future liabilities. Benjamin Graham would verify whether real tax payments are simply being recognized sooner.
-5.75%
Negative yoy SBC growth reduces new equity issuance. Benjamin Graham would verify that enough talent investment remains for growth.
224.19%
Working capital above 30% yoy – Very high. Philip Fisher would demand clarity on whether the buildup is strategic or signals inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
351.62%
AP above 30% yoy – High. Philip Fisher would suspect possible cash strain or very aggressive use of supplier credit.
-1034.42%
A negative yoy shift in other WC might free up cash flow. Benjamin Graham would confirm the items are not essential to operations or revenue generation.
-5.75%
A negative yoy shift in other non-cash items can lower reported volatility. Benjamin Graham would confirm it is not concealing real operational costs or artificially inflating net income.
10.47%
Operating cash flow growth 10-15% – Solid. Seth Klarman would see a healthy sign for near-term liquidity and reinvestment.
90.96%
CapEx above 15% yoy – Significant. Philip Fisher would demand strong evidence of high-ROI projects to offset the spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
90.96%
Above 15% yoy – Heavy. Philip Fisher would require evidence these invests drive future returns and do not hamper free cash flow too much.
-1.15%
A negative yoy figure indicates less repayment or possibly new debt issuance. Benjamin Graham would see rising leverage as a red flag unless expansions have strong returns.
-84.36%
A negative yoy figure could mean fewer or no new shares or even net buybacks. Benjamin Graham would see it as positive unless expansions need capital that internal cash cannot provide.
No Data
No Data available this quarter, please select a different quarter.